Abstract
We report our experience with high-dose chemotherapy (HDC) and autologous SCT (ASCT) in 66 patients out of 113 (113 patients out of 153 had complete analysis) with primary refractory Hodgkin's lymphoma (PR-HL) who received salvage chemotherapy followed by BEAM as HDC. Median age at ASCT was 23 years. Before salvage chemotherapy, stages I:II:III:IV were 2:21:14:29, bulky disease 27%, involvement of mediastinum 79%, spleen 26% and extranodal site 47%; 92% had ESHAP (etoposide, methylprednisolone, high-dose cytarabine, cisplatin) as salvage. Post-ASCT evaluation showed response in 50 patients (76%), complete response (CR) in 37 (56%), partial response in 14 (21%), no response or stable disease in three (5%) and progressive disease in 10 (15%) patients. Six patients achieved CR after XRT (5) or surgery (1), making a total with CR of 43 (65%). From diagnosis and HDC, median follow-up is 38.5 and 22.8 months and median overall survival 78 and 57 months, respectively. EFS and overall survival (OS) are 36 and 64%, respectively. In all 47% patients are in CR. Twenty-two (33%) patients died of the disease. Multivariate analysis showed elevated lactic dehydrogenase (LDH) for EFS (P=0.041) and mediastinal involvement for OS (P=0.038) as ne...Continue Reading
References
Nov 19, 1992·The New England Journal of Medicine·G P CanellosB A Peterson
Feb 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoV T DeVita
Apr 24, 1993·Lancet·D C LinchG V Hudson
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V BonfanteG Bonadonna
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LazarusM M Horowitz
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M AndréC Gisselbrecht
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J W SweetenhamA H Goldstone
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SuredaUNKNOWN Grupo Español de Linformas/Transplante Autólogo de Médula Osea Spanish Cooperative Group
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe FerméGilles Salles
Jun 28, 2002·Lancet·Norbert SchmitzUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Jul 10, 2002·Bone Marrow Transplantation·J CzyzK Warzocha
Feb 12, 2004·British Journal of Haematology·Craig H MoskowitzJoachim Yahalom
Apr 20, 2004·Bone Marrow Transplantation·J CzyzW W Jedrzejczak
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·YeeYie E LieskovskyRajni Agarwal
Mar 2, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A SuredaUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group
May 5, 2005·Blood·Julye C LavoieThomas J Nevill
Dec 6, 2005·Bone Marrow Transplantation·F MorabitoM Federico
Jul 31, 2007·Bone Marrow Transplantation·S AkhtarI Maghfoor
Citations
Nov 3, 2004·International Journal of Radiation Oncology, Biology, Physics·Celia M ViegasLuis Souhami
Sep 12, 2013·PloS One·Shuchi AnandThomas Gaziano
Dec 24, 2016·Tumori·Mouhammed KeltaReyad Dada
Feb 3, 2018·BMC Cancer·Masahiro SekimizuKeizo Horibe
Jul 5, 2019·Pediatric Transplantation·Amr AbdallaAlaa El-Haddad
Jan 22, 2020·International Journal of Hematology·Yuhki KogaKeizo Horibe